Search

Introduction: Plant-based meats (PBM) are an emerging set of food technologies that could reduce the environmental impacts of food systems by mitigating consumer demand for animal products. However, scaling up the production and consumption of plant-based meats requires overcoming multiple technological, regulatory, political, and market barriers. An evidence-based prioritization of needs and actions may help actors (e.g., investors, funders, policymakers) who wish to help scale PBM achieve desired outcomes with limited resources. Research question: What actions could most effectively help to scale up the production and/or consumption of plant-based meat in Brazil? Methods: We selected Brazil as a case study of a country with a significant animal agriculture sector and a burgeoning PBM sector. We constructed a panel of nine experts and employed the Delphi technique during two rounds of an online survey to iteratively assess the degree of consensus and disagreement around the relative priority of 14 possible actions (identified from relevant literature) that could help to scale up the production and/or consumption of PBM in Brazil. We used the Importance, Neglect, and Tractability framework. Results: The panelists collectively concluded that the top priority action for scaling up both the production and the consumption of plant-based meat in Brazil was to reduce the price of products for consumers. For most priority actions, there was greater consensus among panelists in the second round of the survey. Discussion: Our findings contribute to an improved understanding of (a) which actions may be of highest priority for investors, funders, and policymakers, (b) synergies and differences between priority actions to scale up the production versus consumption of PBM in Brazil, (c) the relative merits of focusing on scaling up PBM production versus consumption, and (d) the strengths and limitations of assessing expert opinion on alternative protein futures using the Delphi technique. [ABSTRACT FROM AUTHOR]

Background: Endometrial cancer is of increasing concern in several countries, including Brazil, in part because of an ageing population, declines in fertility, and the increasing prevalence of obesity. Although endometrial tumors had lagged behind other cancer types in terms of treatment improvements, molecular characterization of these tumors is paving the way for novel therapies and an expansion of the therapeutic arsenal. We aimed to help medical oncologists who manage patients with recurrent or metastatic endometrial cancer in the Brazilian healthcare setting. Methods: The panel, composed of 20 medical oncologists, convened in November 2021 to address 50 multiple-choice questions on molecular testing and treatment choices. We classified the level of agreement among panelists as (1) consensus (=75% choosing the same answer), (2) majority vote (50% to <75%), or (3) less than majority vote (<50%). Results: Consensus was present for 25 of the 50 questions, whereas majority vote was present for an additional 23 questions. Key recommendations include molecular testing for every patient with recurrent/metastatic endometrial cancer; choice of first-line treatment according to microsatellite instability and HER2, with the addition of programmed death ligand 1 (PD-L1) and hormone receptors (HRs) for second-line therapy; carboplatin and paclitaxel as the preferred option in first-line treatment of HER2-negative disease, with the addition of trastuzumab in HER2-positive disease; pembrolizumab plus lenvatinib as a key option in second line, regardless of HER2, PD-L1 or HRs; and various recommendations regarding treatment choice for patients with distinct comorbidities. Conclusion: Despite the existing gaps in the current literature, the vast majority of issues addressed by the panel provided a level of agreement sufficient to inform clinical practice in Brazil and in other countries with similar healthcare environments. [ABSTRACT FROM AUTHOR]